Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Teva, MedinCell win FDA approval for slow-release schizophrenia drug Uzedy

Teva, MedinCell win FDA approval for slow-release schizophrenia drug Uzedy
After 20 years developing technology for slow-release injectable drugs, MedinCell of France has won its first FDA approval.

In combination with Teva, MedinCell has scored an FDA nod for Uzedy (risperidone), an extended-release injectable suspension treatment for adults with schizophrenia.

The endorsement comes 12 months after the FDA sent a complete response letter to the companies, rejecting the treatment. Shortly after the companies refiled for approval in November, MedinCell received a 40 million euro ($42 million) loan from the European Investment Bank to continue developing its technology.

“The approval of the first product formulated with our technology is a pivotal moment for MedinCell,” the company’s CEO Christophe Douat said in a release. “Our technology reaching commercial stage marks the start of an exciting new era for MedinCell.”

Uzedy will be available in the U.S. in “the coming weeks” at a wholesale cost of $1,232 to $3,080 per month, depending on the dosage strength, the companies said.

The drug can be administered at one- or two-month intervals. After it is dosed, therapeutic blood concentrations are reached in six to 24 hours, MedinCell said.

Originally developed by Johnson & Johnson and known commercially as Risperdal, the antipsychotic drug was first approved by the FDA 30 years ago. Teva brought a generic version of risperidone to the market more than a dozen years ago.

MedinCell’s BEPO technology—also called SteadyTeq—is based on copolymers and a biocompatible solvent that are formulated along with the active ingredient. After dosing, the ingredient is trapped in a depot that gradually degrades, allowing the drug’s slow release.

Uzedy’s approval is backed by two phase 3 trials. In the RISE study of 544 patients, the one-month regimen of Uzedy reduced the risk of relapse compared with placebo by 80%. The risk reduction associated with the two-month regimen was 63%.

The SHINE study evaluated adverse events with 336 patients and produced similar results to the RISE trial.

Uzedy joins a crowded field of longer-acting schizophrenia drugs, including Otsuka and Lundbeck’s Abilify Asimtufii, which also was approved last week, with its injected dose lasting for two months.

J&J dominates the market with its long-acting schizophrenia drugs that sustain efficacy for three and six months. Last year, J&J’s Invega Sustenna and Invega Trinza franchise racked up sales of $4.1 billion.

Approximately 80% of patients with schizophrenia experience multiple relapses over their first five years of treatment, most commonly because of suboptimal adherence to daily, oral antipsychotics, MedinCell said.

May 2, 2023 

0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies